Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

about

Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.

P2860

Q52315457-35D28B11-85F8-4F87-B173-830B696D5835

P2860

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Item

http://www.wikidata.org/entity/Q49554838

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical Pharmacogenetics Impl ...... CYP2D6 and Tamoxifen Therapy.

@en

Clinical Pharmacogenetics Implementation Consortium

@nl

type

Item

label

Clinical Pharmacogenetics Impl ...... CYP2D6 and Tamoxifen Therapy.

@en

Clinical Pharmacogenetics Implementation Consortium

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... CYP2D6 and Tamoxifen Therapy.

@en

Clinical Pharmacogenetics Implementation Consortium

@nl

P1476

Clinical Pharmacogenetics Impl ...... CYP2D6 and Tamoxifen Therapy.

@en

P2093

Andrea Gaedigk

http://www.w3.org/2001/XMLSchema#string

Hitoshi Zembutsu

http://www.w3.org/2001/XMLSchema#string

Howard L McLeod

http://www.w3.org/2001/XMLSchema#string

James N Ingle

http://www.w3.org/2001/XMLSchema#string

Katrin Sangkuhl

http://www.w3.org/2001/XMLSchema#string

Kelly E Caudle

http://www.w3.org/2001/XMLSchema#string

Matthew P Goetz

http://www.w3.org/2001/XMLSchema#string

Matthias Schwab

http://www.w3.org/2001/XMLSchema#string

Michael Province

http://www.w3.org/2001/XMLSchema#string

Michelle Whirl-Carrillo

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular determinants for the tissue specificity of SERMs

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

PharmGKB summary: tamoxifen pathway, pharmacokinetics

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

P31

scholarly article

P356

10.1002/CPT.1007

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Henk-Jan Guchelaar

Mark J Ratain

P577

2018-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29385237

http://www.w3.org/2001/XMLSchema#string

P932

5931215

http://www.w3.org/2001/XMLSchema#string

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

about

P2860

P2860

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P932